۳۰ درصد تخفیف نوروزی ویژه کارگاه‌ها و فیلم‌های آموزشی

اصول تنظیم قراردادها

پروپوزال نویسی

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus

Alfred Azenabor¹, Anthonia O. Ogbera², Ngozi E. Adejumo³, Adejimi O. Adejare⁴

Abstract

BACKGROUND: Acute Phase Reactants (APRs) have a wide range of activities that contribute to host defense. The aim of this report was to evaluate the dynamics and magnitude of these proteins in various microvascular complications in diabetes mellitus (DM). We also sought to assess the predictive values of APRs and other clinical variables for microvascular complications in DM.

METHODS: This was a case control study carried out in 200 Nigerian subjects with type 2 DM and 100 sex and age matched healthy controls. The studied APRs included C-reactive protein, beta 2 microglobulin, fibrinogen and lipoprotein (a).

RESULTS: The mean values of the APRs were significantly higher in type 2 DM compared with the controls and were observed in higher concentrations in those with microvascular complications, except beta 2 microglobulin. Presence of microvascular complications was observed in those with dilated fundus examination (retinopathy), symptom score of 3.0 (neuropathy), urea and creatinine levels above 50mg% and 1.5mg%, respectively, with significant proteinuria (nephropathy). Significant increase in mean ± SEM values of lipoprotein (a) was observed in diabetic retinopathy in comparison with those without complications (25.76 ± 1.13 mg/dl vs. 22.37 ± 0.73 mg/dl, p = 0.005). Elevated C-reactive protein was observed in diabetic neuropathy in comparison with those without complications (11.43 ± 2.33 u/ml vs. 8.30 ± 1.15 u/ml, p = 0.048). Increased beta 2 microglobulin levels were observed in patients with diabetic foot ulcers in comparison with those without complications (3.04 ± 0.51 mg/dl vs. 2.54 ± 0.14 mg/dl, p = 0.049). Circulating levels of Lipoprotein (a) predicted retinopathy in DM with both good and poor long-term glycemic control while duration of DM predicted the occurrence of foot ulcers.

CONCLUSIONS: Increased level of APRs was associated with a number of microvascular complications and may play a role in the pathogenesis.

KEYWORDS: Acute Phase Reactants, Type 2 Diabetes Mellitus, Microvascular Complications.

Microvascular dysfunctions in diabetes are due to abnormalities in small blood vessels, and particularly affect the retina (diabetic retinopathy) and the kidney (nephropathy). It is equally important to consider the acute phase response, which is a dynamic homeostatic process that involves all the major systems of the body in addition to the immune, cardiovascular and central nervous system. Normally, the acute phase response lasts only a few days. However, in cases of chronic or recurring inflammation, an aberrant continuation of some aspects of the acute phase response may contribute to the underlying tissue damage that accompanies the disease, and also leads to further complica-
Acute phase reactant dynamics and diabetes mellitus

Acute phase reactants have a wide range of activities that contribute to host defense; they can directly neutralize inflammatory agents, help to minimize the extent of local tissue damage, as well as participate in tissue repair and regeneration. Changes in these acute phase reactants are not specific and the non specific nature of the response means that individual proteins are rarely helpful as an aid in diagnosis; though some like C reactive protein have been strongly associated with inflammatory response.

Levels of acute phase reactants have been found to be elevated in adult diabetes, but normal in childhood diabetes, suggesting that the increase could be related to the occurrence of microvascular dysfunctions rather than the diabetes per se. Studies have shown increased levels of acute phase markers in nephropathy and also in patients with microalbuminuria. Increased C-reactive protein (CRP) was observed in Diabetes mellitus. Fibrinogen was reported to be associated with both cardiovascular risk and nephropathy in type 1 and 2 diabetes. Hyperfibrinogenemia was reported in Nigerian diabetics, although there was no sufficient evidence to suggest its role in organ complications. Diabetic patients were also reported to have a higher lipoprotein (a) [Lp(a)] than non diabetic persons. However, data on the status of Lp (a) in Nigerian diabetics is not substantive. Serum beta 2 microglobulin (β2MGB) levels in DM have not been well documented, though the pathophysiology of this acute phase reactant with regards to organ complications is still obscure. An intriguing report had earlier suggested a clinical importance in decreasing this protein. The implication of the changes in the pattern of acute phase reactants in DM with microvascular complications is poorly understood. The aim of this study was to evaluate the dynamics and magnitude of these acute phase reactants in various microvascular dysfunctions of type 2 DM. We also sought to assess the predictive values of APRs and other clinical variables for microvascular complications.

Methods

This was a case control study carried out at the Diabetes Centre of the Lagos State University Teaching Hospital, Ikeja, Lagos State, Nigeria. A total of 200 subjects with type 2 DM and 100 healthy age and sex matched individuals served as controls. The control subjects were volunteer staffs of the hospital and were screened for DM by having them subjected to fasting plasma glucose and glycosylated hemoglobin tests. Venous samples were collected from the antecubital fossa of all the subjects after an overnight fasting (10-14 hours) in a sitting position. Duration of the illness was grouped into early stage (1-5 years) and late stage (greater than 5 years). The DM subjects were being managed with oral hypoglycemic agents and diet at the time of study. The subjects were further subdivided on the basis of presence or absence of microvascular complications. Dip stick urinalysis was carried out on all subjects as well as controls to rule out infective proteinuria when their urine tests were positive for nitrite and leucocytes. Elevated serum urea and creatinine in addition to proteinuria and clinical presentation was used to categorize DM with renal failure due to diabetic nephropathy. Neuropathy was established using the diabetic neuropathy symptom score, using a cut-off point of 3.0. This was based on the ability to respond to three of four questions, which includes queries about numbness to the feet or legs, pricking sensation of the feet or legs, burning or aching of the feet or legs, gait problems and pain. Retinopathy was observed in those with dilated fundus examination. Ethical approval was received from the Ethics and Research Committee of Lagos State University Teaching Hospital. Consent of the patients was gotten through the aid of a well structured questionnaire before the commencement of the study.

Fasting blood samples were collected into tubes containing fluoride oxalate, lithium heparin, EDTA and citrate anticoagulant. Other exclusion criteria for both subjects and controls included those on immunosuppressive drugs, those with systemic diseases, those on steroids,
those with malignancies, heart failure patients, pregnant women, and those who were undergone surgery recently. Excluded subjects were also those with malaria parasite and those positive for rheumatoid arthritis.

Biochemical analysis: C-reactive protein, beta 2 microglobulin and Lp(a) was measured turbidimetrically, while fibrinogen estimation was done using clot weight method of in-gram. Glucose was determined by the glucose oxidase method. The elevated Lp(a) was defined as serum levels above 30 mg/dl, high CRP as levels above 3 mg% and hyperfibrinogenemia as fibrinogen levels of 0.35 mg/l. Elevated β2GMB levels was defined as serum levels above 3 mg%,

**Statistical Analysis**

Data were analyzed using SPSS software version 15 and Epi Info. Independent student’s t-test and chi-square were used to compare groups. Within groups and between groups comparison was done using analysis of variance (ANOVA). Quantitative data are expressed as mean ± standard error of mean (SEM). Probability values of less than 0.05 were considered to be statistically significant (p < 0.05). Logistic regression analysis was used to predict outcomes.

**Results**

The mean duration of DM in the study subjects was 6 ± 0.59 years ranging from 0.1 to 10 years. The mean age of the DM subjects (57.7 ± 0.76 years) and controls (59.6 ± 0.89 years) was comparable (p = 0.8) and the female-male ratio in both was 2:1. The DM free controls had fasting plasma glucose and glycosylated haemoglobin less than 100 mg% and 5.7% respectively. The level of acute phase reactants in diabetic subjects were significantly higher than those in control group (Table 1).

The prevalence of microvascular complications in the 200 diabetic participants were as follows: retinopathy 20% (n = 40), neuropathy 31% (n = 62), nephropathy with renal failure 1% (n = 2), and foot ulcers 7.5% (n = 15). Within group and between group analysis using one way ANOVA showed that increased levels of the acute phase reactants were observed in DM subjects with microvascular complications in contrast to those without microvascular complications as well as the controls, except for beta 2 microglobulin (Table 2). The acute phase reactant concentrations were observed to be lower in DM with shorter duration of illness (less than five years) when compared with those of longer duration, except CRP (10.04 ± 1.22 Vs 7.94 ± 1.50, p = 0.285). Using relevant cut-off points where applicable; retinopathy was detected in 78% and 53% of subjects with elevated Lp(a) and CRP, respectively; neuropathy was seen in 68% of subjects with elevated CRP and presence of foot ulcers was observed in 77% of participants with elevated β2 MGB (Table 3).

| Acute phase reactants | DM Patients mean± SEM \(n = 200\) | Controls mean± SEM \(n = 100\) | t  | P-value |
|-----------------------|-----------------------------------|---------------------------------|----|---------|
| C-reactive protein (u/ml) | 9.27 ± 0.95 | 3.37 ± 0.20 | 4.400 | <0.001 |
| Beta 2 microglobulin (mg/ml) | 2.58 ± 0.09 | 1.63 ± 0.05 | 6.904 | <0.001 |
| Fibrinogen (g/dl) | 1.93 ± 0.04 | 1.23 ± 0.05 | 11.054 | <0.001 |
| Lipoprotein(a) (mg/dl) | 23.05 ± 0.48 | 18.81 ± 0.59 | 5.280 | 0.001 |
| Urea (mg%) | 44 ± 0.97 | 35 ± 1.00 | 0.980 | 0.244 |
| Creatinine (mg%) | 1.30 ± 0.02 | 0.90 ± 0.04 | 0.7450 | 0.200 |
Table 2. Comparison of diabetic patients without microvascular complications, diabetic patients with microvascular complications and control subjects.

| Acute phase reactants               | Controls (n = 100) | DM with microvascular complications (n = 81) | DM without microvascular complications (n = 119) | f     | P-values |
|-------------------------------------|--------------------|---------------------------------------------|-------------------------------------------------|-------|----------|
| C-reactive protein (u/ml)            | 3.37 ± 0.20        | 8.88 ± 1.22                                 | 9.74 ± 1.47                                     | 9.819 | <0.001   |
| Beta 2 microglobulin (mg/ml)         | 1.63 ± 0.05        | 2.51 ± 0.14                                 | 2.67 ± 0.13                                     | 0.990 | 0.373    |
| Fibrinogen (g/dl)                   | 1.23 ± 0.05        | 1.87 ± 0.04                                 | 2.05 ± 0.05                                     | 60.062 | <0.001   |
| Lipoprotein(a) (mg/dl)              | 18.84 ± 0.60       | 22.63 ± 0.70                                | 23.62 ± 0.68                                    | 14.50 | <0.001   |

The proportion of DM patients with good long term glycemic control as reflected in their glycosylated hemoglobin was 68% while 32% had poorly controlled glycemia. Logistic regression analysis of the APRs with various microvascular complications showed that Lp(a) only predicted retinopathy in those with good glycemic control (odds ratio = 1.065, 1.005 to 1.128 95% confidence interval, p = 0.03) as well as in those with poor glycemic control (odds ratio = 1.073, 1.015 to 1.134 95% confidence interval, p = 0.013). The duration of DM also predicted development of foot ulcers (Tables 5 and 6).

Discussion
In this study, the APRs of type 2 DM were all significantly higher than the control group and the concentrations were higher in complicated DM, except for β2MGB. Increased level of CRP observed in this study was in agreement with previous report. This is indicative of inflammation and tissue damage. Hyperfibrinogenemia observed in Nigerian Diabetics is in consonance with some previous studies. The adverse effect of this may lead to an imbalance in homeostatic mechanism and may further degenerate to a hypercoagulable state. In addition, elevated Lp(a) levels could be a pointer to cardiovascular predisposition, which conveys the impression that these patients are more prone to atherogenesis than the control cases. This molecule carries a protein that may deter the body’s ability to dissolve blood clots and it is under investigation as either a marker or cause of heart disease. Lp(a) appears to be poorly cleared from the plasma and is strongly and independently associated with atherosclerosis. The homology of Lp(a) with plasminogen has led to the hypothesis that it somehow interferes with plasminogen activation and thus impairs fibrinolysis. Until recently, much interest has been focused on Lp(a), which is a complex lipoprotein consisting of lipids, carbohydrates and two larger apoproteins, (b) and (a).

CRP demonstrated a positive relationship with fasting blood glucose. This in comparison with other APRs responded earlier to the glucotoxic microenvironment created in DM. The duration of DM did not affect the pattern of expression of the APRs, only CRP was observed to be insignificantly elevated; this may be as a result of being an early marker of inflammation. This was in contrast to other APRs which could thus be regarded as the late inflammatory markers.

Table 3. Prevalence of elevated acute phase reactants in various microvascular complications.

| Microvascular Complications | CRP | β2MGB | Lp(a) | Fibrinogen |
|-----------------------------|-----|-------|-------|------------|
| Retinopathy                 | 53% | 28%   | 79%   | 28%        |
| Neuropathy                  | 68% | 31%   | 23%   | 26%        |
| Foot Ulcers                 | 53% | 67%   | 20%   | 38%        |
| Nephropathy                 | 34% | 39%   | 43%   | 44%        |

LP(a), Lipoprotein (a); β2MGB, Beta 2 microglobulin; CRP, C-Reactive protein
A cute phase reactant dynamics and diabetes mellitus

Table 4. Logistic regression analysis of acute phase reactants in type 2 DM with good long-term glycemic control (HBA1c < 7%) and various microvascular complications.

| Acute phase reactants | Retinopathy OR (95% CI) | P-value | Neuropathy OR (95% CI) | P-value | Foot ulcers OR (95% CI) | P-value | Nephropathy OR (95% CI) | P-value |
|-----------------------|------------------------|---------|------------------------|---------|------------------------|---------|------------------------|---------|
| CRP                   | 1.018                  | 0.220   | 1.005                  | 0.689   | 1.014                  | 0.486   | 1.003                  | 0.927   |
| (0.989-1.047)         |                       |         | (0.979-1.03)           |         | (0.974-1.056)          |         | (0.927-1.018)          |         |
| B2MGB                 | 0.770                  | 0.147   | 1.106                  | 0.482   | 1.601                  | 0.148   | 1.259                  | 0.579   |
| (0.541-1.096)         |                       |         | (0.836-1.46)           |         | (0.846-3.023)          |         | (0.558-2.84)           |         |
| Lp(a)                 | 1.065                  | 0.03*   | 0.978                  | 0.405   | 0.981                  | 0.753   | 0.972                  | 0.1752  |
| (1.005-1.128)         |                       |         | (0.927-1.03)           |         | (0.872-1.10)           |         | (0.817-1.15)           |         |
| Fibrinogen            | 0.769                  | 0.494   | 1.272                  | 0.496   | 0.388                  | 0.220   | 2.17                   | 0.476   |
| (0.362-1.631)         |                       |         | (0.637-2.54)           |         | (0.873-1.10)           |         | (0.259-18.0)           |         |
| Sex                   | 1.519                  | 0.600   | 0.444                  | 0.244   | 2.673                  | 0.251   | 0.000                  | 0.989   |
| (0.318-7.246)         |                       |         | (0.113-1.74)           |         | (0.499-14.29)          |         | (0.000-0.00)           |         |
| Age                   | 1.160                  | 0.846   | 1.334                  | 0.630   | 0.803                  | 0.806   | 0.000                  | 0.988   |
| (0.285-5.217)         |                       |         | (0.413-4.30)           |         | (0.139-4.619)          |         | (0.000-0.00)           |         |
| Duration              | 1.386                  | 0.775   | 0.924                  | 0.922   | 1.014                  | 0.991   | 0.000                  | 0.983   |
| (0.149-12.92)         |                       |         | (0.191-4.48)           |         | (0.102-10.11)          |         | (0.000-0.00)           |         |

LP(a), Lipoprotein (a); B2MGB, Beta 2 microglobulin; CRP, C-Reactive protein; OR, Odds Ratio; CI, Confidence Interval

Of importance to note is that these APRs may be strongly linked to the pathogenesis of organ complications in DM. Lp(a) levels was observed to be significantly raised in diabetic patients with retinopathy. This observation agrees with previous study by Khare et al. Increased advanced glycation end products may account for the increased risk of diabetic complications in patients with higher Lp(a) values. A recent study showed that the levels of APRs correlated with the number of microvascular complications; however, their study did not look at retinopathy but at microvascular complications in general. In this research, a detailed study of APRs was made and thus was able to also observe increased CRP in diabetic neuropathy with a percentage of 53%, increased B2MGB in foot ulcers (67%) and elevated Lp(a) in retinopathy (72%). B2MGB has been found to be associated with falling CD4 count in HIV seropositive individuals, suggesting a close association with suppressed immunity. Increased activation or destruction of lymphocytes raises B2MGB levels.

Table 5. Logistic regression analysis of acute phase reactants in type 2 DM Patients with poor long-term glycemic control (HBA1c > 7%) and various microvascular complications.

| Acute phase reactants | Retinopathy OR (95% CI) | P-value | Neuropathy OR (95% CI) | P-value | Foot ulcers OR (95% CI) | P-value | Nephropathy OR (95% CI) | P-value |
|-----------------------|------------------------|---------|------------------------|---------|------------------------|---------|------------------------|---------|
| CRP                   | 1.004                  | 0.909   | 1.028                  | 0.239   | 0.955                  | 0.251   | 0.994                  | 0.999   |
| (0.942-1.069)         |                       |         | (0.982-1.078)          |         | (0.839-1.088)          |         | (0.000-17.6)           |         |
| B2MGB                 | 1.177                  | 0.561   | 0.936                  | 0.756   | 1.578                  | 0.676   | 0.217                  | 0.998   |
| (0.679-2.041)         |                       |         | (0.615-1.423)          |         | (0.724-3.440)          |         | (0.000-0.00)           |         |
| Lp (a)                | 1.073                  | 0.01*   | 1.009                  | 0.497   | 0.969                  | 0.676   | 0.832                  | 0.998   |
| (1.015-1.134)         |                       |         | (0.984-1.035)          |         | (0.839-1.120)          |         | (0.000-3.37)           |         |
| Fibrinogen            | 0.941                  | 0.908   | 1.332                  | 0.501   | 1.143                  | 0.847   | 0.109                  | 0.998   |
| (0.337-2.626)         |                       |         | (0.578-3.068)          |         | (0.293-4.461)          |         | (0.000-0.00)           |         |
| Sex                   | 1.791                  | 0.188   | 1.982                  | 0.101   | 0.803                  | 0.987   | 0.000                  | 0.790   |
| (0.725-4.261)         |                       |         | (0.876-4.48)           |         | (0.159-4.044)          |         | (0.000-0.00)           |         |
| Age                   | 0.655                  | 0.490   | 0.802                  | 0.690   | 2.284                  | 0.367   | 4.112                  | 0.326   |
| (0.196-2.179)         |                       |         | (0.271-2.37)           |         | (0.379-13.76)          |         | (0.244-69)             |         |
| Duration              | 2.003                  | 0.288   | 0.883                  | 0.819   | 0.125                  | 0.016   | 580E+0.03              | 0.985   |
| (0.556-7.221)         |                       |         | (0.304-2.56)           |         | (0.023-0.683)          |         | (0.000-0.00)           |         |

LP(a), Lipoprotein (a); B2MGB, Beta 2 microglobulin; CRP, C-Reactive protein; OR, Odds Ratio; CI, Confidence Interval

1302

J Res Med Sci / October 2011; Vol 16, No 10.
Since $\beta$2MGB is essential for the expression of major histocompatibility complex (MHC) antigens, its stimulation enhances the recognition of bacteria in association with MHC. This could have also being stimulated in response to bacteria which are causative agents in most foot ulcers, and may thus be very vital in combating infectious agents. Our observation agreed with a previous study which observed circulating levels of APRs to be associated with amputation risk of diabetic foot ulcers and thus could aid clinicians in the management of diabetic foot syndromes.

Logistic regression analysis was carried out to evaluate the possibility of using acute phase reactants and other clinical variables in predicting the future development of microvascular complications in DM patients yet to have microvascular complications. This was assessed in DM patients with good long-term glycemic control (HBA1c < 7%) as well as in those with poor long-term glycemic control (HBA1c > 7%). The independent variables entered into the model included the acute phase reactants, sex, age and duration of illness, while the various microvascular complications served as the dependent variables. In this study, Lp(a) only predicted retinopathy in DM with both good and poor long-term glycemic control. It should be emphasized that in addition to Lp(a) being an independent indicator of the risk of vascular disease development, increased levels of this protein proved to be a strong predictor of retinopathy in DM patients as observed in this study. The level of Lp(a) is genetically determined, and when elevated, cannot be lowered by alterations in food intake or by most of the cholesterol lowering agents. This entity could also contribute to the genetic predisposition of some DM patients to complications regardless of good glycemic control.

It was noted that age had no relationship with the occurrence of microvascular complications; rather the duration of the illness that predicted the future development of foot ulcers. This may be secondary to sensory neuropathic changes. Every part of the peripheral nervous system is vulnerable to diabetic involvement. Minor reversible damage can be identified early while late complications as manifested by numbness (anesthesia) and abnormal sensation (paresthesia) and leading to foot ulceration is very common.

**Conclusion**

Increased levels of APRs correlate with a number of microvascular complications and may play a role in the pathogenesis.

**Acknowledgement**

We wish to acknowledge Miss MC Bello who assisted with data collation and manuscript typing.

**Conflict of Interests**

Authors have no conflict of interests.

**Authors' Contributions**

AA designed the study, participated in the data collation, statistical analysis, funding and writing the draft of the manuscript. OAO participated in the study, subjects selection, funding and data collation. NEA and AOA participated in the study and data collation.

**References**

1. Crook MA, Tutt P, Simpson H, Pickup JC. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin Chim Acta 1993; 219(1-2): 131-8.
2. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40(11): 1286-92.
3. McMillan DE. Further observations on serum viscosity changes in diabetes mellitus. Metabolism 1982; 31(3): 274-8.
A cute phase reactant dynamics and diabetes mellitus   Azenabor et al

4. Bergsrand CG, Furst P, Larsson Y, Sterky G. Serum haptoglobin in juvenile diabetes. Scand J Clin Lab Invest 1962; 14: 629-32.

5. Ganrot PO, Gydell K, Ekelund H. Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) 1967; 55(3): 537-44.

6. Schalkwijk CG, Poland DC, van DW, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42(3): 351-7.

7. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19(12): 3071-8.

8. Okeoghen O, Azenabor A. Glycaemic indices and non-traditional biochemical cardiovascular disease markers in a diabetic population in Nigeria. J Coll Physicians Surg Pak 2011; 21(8): 455-9.

9. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003; 26(7): 2150-5.

10. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, et al. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003; 26(5): 1439-48.

11. Haffner SM, Tuttle KR, Rainwater DL. Lack of change of lipoprotein (a) concentration with improved glycaemic control in subjects with type II diabetes. Metabolism 1992; 41(2): 116-20.

12. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 1992; 117(1): 42-7.

13. Clodi M, Oberbauer R, Bodlaj G, Hofmann J, Maurer G, Kostner K. Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients. Metabolism 1999; 48(3): 369-72.

14. Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 2009; 24(2): 571-7.

15. Meijer JW, Smit AJ, Sonden EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002; 19(11): 962-5.

16. INGRAM GI. A suggested schedule for the rapid investigation of acute haemostatic failure. J Clin Pathol 1961; 14: 356-60.

17. Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972; 97(151): 142-5.

18. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98(10): 2980-7.

19. Pu LJ, Lu L, Xu XW, Zhang RX, Zhang Q, Zhang JS, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006; 5: 27.

20. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D’Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 125(8): 653-7.

21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-86.

22. Ogbera AO, Azenabor AO. Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM. Diabetet Metab Syndr 2010; 2: 51.

23. Famodu AA, Ojogwu LI, Jayiesimi AEA, Okpere B, Laewor, M. Effect of insulin therapy of fibrinolytic activity in Nigerians with insulin dependent diabetes. International Diabetes Digest 1999: 668–9.

24. Reid HL. Sex variation in plasma fibrinogen levels in Enugu, Nigeria. West Afr J Med 1984; 3: 195-9.

25. Utterman G. Lipoprotein (a): A genetic risk factor for premature coronary heart disease. Curr Opin Lipidol 1990; 1: 404 –10.

26. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990; 85(6): 1709-15.

27. Khare K C, Ramakrishna P, Bhatnagar AD, Bhavsar R. Serum Lp(a) levels in patients of Diabetes Mellitus. Int J Diab Dev Countries 2000; 20: 79–83.

28. Guerci B, Meyer L, Sommer S, George JL, Ziegler O, Drouin P, et al. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. Diabetes Metab 1999; 25(5): 412-8.
29. Rema M, Mohan V, Snehalatha C. Acute phase serum proteins in diabetic retinopathy. Indian J Ophthalmol 1996; 44(2): 83-5.
30. Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanabe Y, et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J 2000; 64(1): 51-6.
31. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80(5): 1313-9.
32. Laycock JF, Lee J, Wise PH. Essential Endocrinology. 2nd ed. Oxford: Oxford University Press; 1983. p. 299-306.
30 درصد تخفیف نوروزی ویژه کارگاه‌ها و فیلم‌های آموزشی

اصول تنظیم قراردادها
پروپوزال نویسی
آموزش مهارت های کاربردی در ندوین و چاپ مقاله